This venture capital firm focuses on breakthrough technologies transforming healthcare and typically invests at the pre-seed, seed, and pre-Series A stages. The firm is backed by limited partners from within the healthcare industry, reinforcing its domain expertise and strategic alignment with clinical innovation.
The firm targets early-stage life science startups working at the intersection of cutting-edge science and healthcare applications. Areas of interest include genomic technologies, synthetic biology, digital health, machine learning and artificial intelligence, therapeutics, and diagnostics. In therapeutics, the firm focuses on pre-IND assets, while for technologies regulated as medical devices, the firm prioritizes smart devices at the pre-commercial stage.
With a team that brings a strong clinical perspective, the firm actively supports its portfolio companies through clinical development and has a history of helping academic scientists translate research into commercial ventures.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.





Leave a comment